Chimeric antigen receptor (CAR) T-cells have demonstrated promising efficacy, particularly inhematologic malignancies. A challenge to CAR T-cells in solid tumors is the immunosuppressivetumor microenv
Immunology-based interventions have been proposed as a promising curative chance to effectively attack postoperative minimal residual disease and distant metastatic localizations of prostate tumors. W
Inhibiting the androgen receptor (AR), a ligand-activated transcription factor, with androgen deprivation therapy is a standard-of-care treatment for metastatic prostate cancer (PCa). Paradoxically, a
IntroductionProstate cancer is one of the most commonly diagnosed malignancies in men with high mortality rates. Despite the recent therapeutic advances, such as immunotherapies, survival of patients
